Susvimo is designed to provide continuous drug release into the vitreous through Roche’s Contivue implant
The CHMP’s positive opinion was supported by data from KALOS and LOGOS
State's Pharma Park at Nava Raipur gains momentum as policy reforms and ease-of-doing-business initiatives drive investor confidence
The investment of Rs. 110 crore made in Biodeal during 2024 has now been fully redeemed, delivering returns above the Fund’s expectations
Sculptra uses a unique formulation to stimulate the body’s own collagen production, helping rebuild the skin’s underlying structure and address collagen loss associated with ageing
The successful inspection marks another regulatory milestone for the company's analytical operations, reinforcing its commitment to quality, regulatory compliance, and data integrity across its global analytical network
The two-day debut event is expected to attract more than 2,500 attendees, 120 exhibitors, and participants from over 40 countries
The milestone represents a first regulatory achievement for Asymchem’s DH2 carbapenem site
Diagnostic major expands profit and strategic footprint
EBITDA rises 39%, adjusted PAT jumps 72%; biologics CDMO business expands with new global biosimilar customer
Royalty-free agreement covers supply of generic HIV prevention drug to 129 low- and middle-income countries, subject to regulatory approvals
Transaction moves closer to completion, pending regulatory approvals and other customary closing conditions
Life sciences giant posts USD 11.99 billion in quarterly revenue, beats analyst estimates and lifts full-year revenue and profit guidance
CDMO business drives record growth
Acquisition of manufacturing facilities in Uttarakhand and Uttar Pradesh strengthens Akums' CDMO capabilities in skincare, wellness, hair care and marks its entry into colour cosmetics.
The company’s One India business recorded its highest-ever quarterly sales, growing 12% year-on-year, while the overall chronic portfolio mix improved to 60.4% in the market
Aims to accelerate drug development and clinical manufacturing support
The company posted sales of CHF 3.4 billion in H1 2026, representing 16.0% growth at constant exchange rates (CER) and 11.2% growth at actual exchange rates
Earnings rebound 97% sequentially despite North America pressure
Subscribe To Our Newsletter & Stay Updated
